Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
A significant proportion of healthcare professionals still tend to favor branded drugs
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Subscribe To Our Newsletter & Stay Updated
